MDM2 and prostate cancer: In the present meta-analysis, a significantly decreased risk was found between MDM2 SNP285 polymorphism and ovarian cancer, and a much lower OR was found for breast cancer than that for male cancers (lung and prostate cancer), which was consistent with previous studies.